July 31, 2019
Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update
~ KEVEYIS®(dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~
~ Company on Track to Meet Full-Year 2019 KEVEYIS® Revenue Guidance of $18 to $20 Million ~
~ ...
Read more
Read more
July 31, 2019
Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 31, 2019
Press release - Non-regulatory
Oslo, Norway, 31 July 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activ...
Read more
Read more
July 29, 2019
Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress
- Updated Interim Analysis from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer-
SEATTLE, WA and SAN LEANDRO, CA, July 29, 2019—Rainier Therapeutics, Inc., a privately he...
Read more
Read more
July 25, 2019
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report
Lund, Sweden, 08.00 am CET, 25 July 2019 – BONESUPPORT™, listed on Nasdaq Stockholm - BONESUPPORT HOLDING AB (publ) - listed on Nasdaq Stockholm - an emerging lead...
Read more
Read more
July 24, 2019
GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update
Paris, France, July 24, 2019, 5.45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developin...
Read more
Read more
July 23, 2019
MIPS INTERIM REPORT JANUARY – JUNE 2019
APR -JUN
Net sales increased by 49% to SEK 82.6m (55.6). During the quarter, the organic growth was 38%
Operating profit increased to SEK 36.8m (21.7). The adjusted operati...
Read more
Read more
July 16, 2019
Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
July 15, 2019
Press release - Non-regulatory
Oslo, Norway, 15 July 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnol...
Read more
Read more
July 12, 2019
GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule
Paris, France, July 11, 2019, 5.45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developin...
Read more
Read more
July 11, 2019
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)
11.07.2019 14:32
Oslo, Norway, 11 July 2019
Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of...
Read more
Read more
July 11, 2019
Orexo Interim Report Q2 2019
Improving all fundamentals
Q2 2019 highlights
Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 3...
Read more
Read more